The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.06
Ask: 2.14
Change: 0.005 (0.23%)
Spread: 0.08 (3.883%)
Open: 2.10
High: 2.15
Low: 2.10
Prev. Close: 2.145
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of major interests in shares

11 Oct 2010 14:30

RNS Number : 1948U
Immupharma PLC
11 October 2010
 



For immediate release

11 October 2010

 

Immupharma plc

 

TR-1: Notification of major interests in shares

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

 

Immupharma plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

Pictet Overseas Trust Corporation Limited

4. Full name of shareholder(s)  (if different from 3.):

See Above

 

5. Date of the transaction and date on which the threshold is crossed or reached:

 

6th October 2010

6. Date on which issuer notified:

7th October 2010

7. Threshold(s) that is/are crossed or reached:

 

3%

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

 

Ordinary Shares GB0033711010

2,020,000

2,020,000

2,461,000

2,461,000

0

3.02%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

 

Expiration date

 

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

 

% of voting rights

N/A

N/A

N/A

N/A

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

 

 

Exercise price

 

Expiration date

 

Exercise/ Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

N/A

N/A

N/A

N/A

 

N/A

 

Nominal

Delta

N/A

N/A

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,461,000

3.02%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Not Applicable

14. Contact name:

Katrina Montgomery, Legal & Compliance, Pictet Overseas Trust Corporation Limited

15. Contact telephone number:

+1 242 302 22 22

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLXFLFFBBFBFBZ
Date   Source Headline
19th May 20107:01 amRNSInitiation Of Phase I/IIA Studies In Cancer
19th May 20107:00 amRNSPreliminary Results
8th Apr 20109:26 amRNSBest Drug Development Company in Europe Award
5th Jan 20103:00 pmRNSAdditional Listing
5th Jan 20107:00 amRNSING take 4% stake in ImmuPharma plc
3rd Dec 20097:00 amRNSR&D Symposium at the CNRS in Paris
19th Nov 20097:00 amRNSPositive Final Lupuzor Trial Results
19th Oct 200910:31 amRNS'Best Technology 2009' Award at the AIM Awards
9th Oct 200910:14 amRNSAppointment of Joint Broker
29th Sep 20097:00 amRNSInterim Results
21st Sep 20099:55 amRNS8th Annual Bio Investor Forum
17th Sep 20097:00 amRNSJMP Healthcare Focus Conference
24th Jul 200912:12 pmRNSResult of AGM
23rd Jul 20094:17 pmRNSDirectors' Dealings
30th Jun 20097:00 amRNSAnnual Report and Accounts
24th Jun 20097:00 amRNSPreliminary Results
17th Jun 20097:00 amRNSPiper Jaffray Europe Conference
23rd Mar 20097:00 amRNSDirectors' Dealings
4th Feb 200912:32 pmRNSShare Options
2nd Feb 20092:33 pmRNSCephalon license exercise
30th Jan 20097:00 amRNSSuccessful trial results
22nd Dec 200812:00 pmRNSfurther instalment of grant
25th Nov 20087:00 amRNSOption Agreement with Cephalon
12th Nov 20087:00 amRNSGrant Award
21st Oct 20089:31 amRNSPatents Granted
17th Oct 20084:22 pmRNSAdditional Listing and Total Voting Rights
25th Sep 20087:00 amRNSInterim Results
5th Aug 20083:44 pmRNSAGM Result
10th Jul 20087:00 amRNSSecond Placing
2nd Jul 20087:30 amRNSToxicology study
2nd Jul 20087:00 amRNSFund Raising
30th Jun 20083:00 pmRNSAnnual Report and Accounts
20th May 20087:00 amRNSPre-clinical Data
13th May 20086:00 amRNSTrademark Approval
8th May 20087:00 amRNSPreliminary Results
26th Feb 20087:00 amRNSPhase IIb Trial of IPP-201101
8th Jan 20087:00 amRNSNovel Drug Candidate
18th Dec 200712:51 pmRNSDirectors' Dealings
6th Dec 20077:01 amRNSInitiation of Phase IIb trial
16th Nov 200712:28 pmRNSAppointment of Nomad
28th Sep 20077:02 amRNSInterim Results
22nd Aug 20077:00 amRNSCompound Discovery
20th Aug 200710:17 amRNSAIM Rule 26
13th Aug 20074:17 pmRNSDirectors' Dealing
6th Aug 20072:40 pmRNSGrant of Options
10th Jul 20077:01 amRNSPivotal phase II/III trial
13th Jun 20072:00 pmRNSAGM and Board Update
1st May 20077:02 amRNSPreliminary Results
27th Apr 20074:02 pmRNSBoard Appointment
15th Feb 20077:01 amRNSAppointment of adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.